Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Use of Denosumab in a Patient with Non–Small-Cell Lung Cancer and Severe Renal Function Impairment

Use of Denosumab in a Patient with Non–Small-Cell Lung Cancer and Severe Renal Function... CASE REPORT Use of Denosumab in a Patient with Non–Small-Cell Lung  Cancer and Severe Renal Function Impairment E. Govaerts, MD and J. Vansteenkiste, MD, PhD 71-year-old man was admitted with a 2-month history skeletal-related events in patients with solid tumors with bone A of back pain, weakness, and dyspnea. Medical history metastases. The mode of action is inhibition of the receptor reports immunoglobulin A nephropathy resulting in renal activator of nuclear factor kappa-B ligand (RANKL) respon- transplantation at the age of 47. He redeveloped severe chronic sible for formation, function, and survival of the osteoclast. renal insufficiency based on allograft rejection, with a current Whether denosumab also has direct antitumor effects is Cockroft–Gault creatinine clearance of 24 ml/min and second- unclear. RANKL expression has been documented in several XXX ary hyperparathyroidism. cancer cell lines. The role of RANKL in tumor migration and Positron emission tomography–computed tomography invasion in lung cancer is being examined. In mice, RANKL scan shows a 25-mm tumor of the left upper lobe, malignant mediastinal lymph nodes, and extensive bone metastases (Fig. 1). Pathologic finding reports epidermal growth factor receptor wild-type nonsquamous non–small-cell lung cancer on peripheral bronchoscopic biopsy. Chronic renal impair- ment impedes use of chemotherapy. Denosumab 120 mg was administered subcutaneously for diffuse bone disease, along with http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Journal of Thoracic Oncology Wolters Kluwer Health

Use of Denosumab in a Patient with Non–Small-Cell Lung Cancer and Severe Renal Function Impairment

Vansteenkiste, J.
Journal of Thoracic Oncology , Volume 8 (6) – Jun 1, 2013
Download PDF
2 pages

Loading next page...
 
/lp/wolters-kluwer-health/use-of-denosumab-in-a-patient-with-non-ndash-small-cell-lung-cancer-x1oi7CDTCk

References

References for this paper are not available at this time. We will be adding them shortly, thank you for your patience.

Copyright
Copyright © 2013 by the International Association for the Study of Lung Cancer
ISSN
1556-0864
DOI
10.1097/JTO.0b013e318284375c
pmid
23676561
Publisher site
See Article on Publisher Site

Abstract

CASE REPORT Use of Denosumab in a Patient with Non–Small-Cell Lung  Cancer and Severe Renal Function Impairment E. Govaerts, MD and J. Vansteenkiste, MD, PhD 71-year-old man was admitted with a 2-month history skeletal-related events in patients with solid tumors with bone A of back pain, weakness, and dyspnea. Medical history metastases. The mode of action is inhibition of the receptor reports immunoglobulin A nephropathy resulting in renal activator of nuclear factor kappa-B ligand (RANKL) respon- transplantation at the age of 47. He redeveloped severe chronic sible for formation, function, and survival of the osteoclast. renal insufficiency based on allograft rejection, with a current Whether denosumab also has direct antitumor effects is Cockroft–Gault creatinine clearance of 24 ml/min and second- unclear. RANKL expression has been documented in several XXX ary hyperparathyroidism. cancer cell lines. The role of RANKL in tumor migration and Positron emission tomography–computed tomography invasion in lung cancer is being examined. In mice, RANKL scan shows a 25-mm tumor of the left upper lobe, malignant mediastinal lymph nodes, and extensive bone metastases (Fig. 1). Pathologic finding reports epidermal growth factor receptor wild-type nonsquamous non–small-cell lung cancer on peripheral bronchoscopic biopsy. Chronic renal impair- ment impedes use of chemotherapy. Denosumab 120 mg was administered subcutaneously for diffuse bone disease, along with

Journal

Journal of Thoracic Oncology – Wolters Kluwer Health

Published: Jun 1, 2013

References

  • Acute tumor lysis syndrome - a rare complication in the treatment of solid tumors
    Coiffier
  • The tumor lysis syndrome
    Howard
  • Molecular pathways: osteoclast-dependent and osteoclast-independent roles of the RANKL/RANK/OPG pathway in tumorigenesis and metastasis
    Dougall
  • RANKL inhibition blocks lung cancer-induced osteolytic lesions and reduces skeletal tumor burden in both RANK-expressing and RANK-negative lung cancers
    Miller
  • Overall survival improvement in patients with lung cancer and bone metastases treated with denosumab versus zoledronic acid: subgroup analysis from a randomized phase 3 study
    Scagliotti
  • Effects of denosumab on fracture and bone mineral density by level of kidney function
    Jamal